Country for PR: United Kingdom
Contributor: PR Newswire Europe
Tuesday, January 04 2022 - 20:00
Alamar Biosciences partners with Abcam to drive understanding of the human proteome
FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire-AsiaNet/ --

Alamar Biosciences (Alamar), a platform company focused on transforming the 
field of proteomics to enable the early detection of cancer and other diseases, 
and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences 
research tools, today announced a strategic partnership to further 
understanding of the human proteome.

The field of proteomic analysis is in the spotlight.  Its advance not only 
enhances the understanding of fundamental biology, but also sheds light on the 
status of human health and disease. A deeper understanding of the proteome is 
set to play a crucial role in enabling the next wave of innovations in 
research, diagnostics and therapeutics. Powering this effort requires new 
technology platforms that are able to address the two essential goals in 
proteomic analysis, namely the ability to go as deeply as possible to detect 
very low abundance proteins and the ability to profile thousands of proteins in 
a single sample. 

Dr. Yuling Luo, Founder & CEO of Alamar, commented: "Alamar is working to 
enable the early detection of cancer and other diseases by simultaneous 
measurement of hundreds to thousands of targets, even those present in minute 
amounts. We are very happy to partner with Abcam to access their extensive 
portfolio of recombinant monoclonal antibody pairs, which will accelerate our 
ability to bring our proteomic discovery tools to researchers."

"We are excited to be partnering with Alamar as they develop an automated 
proteomics platform that has the potential to offer unprecedented combination 
of sensitivity, plex-level and dynamic range," commented Dr Emma Sceats, SVP 
Sales, Service and Business Development at Abcam. "The NULISA technology 
platform will provide an important tool for life science research, 
pharmaceutical development and diagnostics, enhancing understanding of the 
circulating proteome and supporting low abundance biomarker discovery. Such 
capability will be critical for the discovery and measurement of many proteins 
in human plasma and other samples that are currently undetectable." 

Abcam's portfolio of over 1,300 fit-for-purpose recombinant antibody pairs is 
actively curated to ensure that it is representative of the key disease areas 
of interest. Designed to enhance biomarker discovery and support deeper 
understanding of the circulating proteome, the portfolio has been pre-validated 
specifically for multiplex applications.

About Alamar Biosciences 

Alamar Biosciences is a privately held life sciences company with a mission to 
transform the field of proteomics to enable the early detection of cancer and 
other diseases. The company's two proprietary technology platforms, NULISA™ and 
Attobody™, work seamlessly with the latest advances in genomics to achieve 
single-digit attomolar detection sensitivity, greatly surpassing the most 
sensitive protein detection technology on the market today. The Attobodies have 
picomolar affinity and built-in high specificity and have the potential to 
expand antibody therapeutics to many targets intractable with conventional 
antibodies. For more information, please visit

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes 
high-quality biological reagents and tools that are crucial to research, drug 
discovery and diagnostics. Working across the industry, the Company supports 
life scientists to achieve their mission, faster. 

Abcam partners with life sciences organizations to co-create novel binders for 
use in drug discovery, in vitro diagnostics and therapeutics, driven by the 
Company's proprietary discovery platforms and world-leading antibody expertise. 

By constantly innovating its binders and assays, Abcam is helping advance the 
global understanding of biology and causes of disease, which enables new 
treatments and improved health. The Company's pioneering data-sharing approach 
gives scientists increased confidence in their results by providing validation, 
user comments and peer-reviewed citations for its 90,000 products. 

With 14 sites globally, many of Abcam's over 1,600-strong team are located in 
the world's leading life sciences research hubs, complementing a global network 
of service and support. 

To find out more, please visit and


Source: Alamar Biosciences and Abcam